Centessa Pharmaceuticals PLC reports results for the quarter ended December 31 - Earnings Summary

• Centessa Pharmaceuticals PLC CNTA.OQ reported a quarterly adjusted loss of 48 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -58 cents. The mean expectation of twelve analysts for the quarter was for a loss of 38 cents per share. Wall Street expected results to range from -42 cents to -32 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Centessa Pharmaceuticals PLC's reported EPS for the quarter was a loss of 48 cents​.

• The company reported a quarterly loss of $66.16 million.

• Centessa Pharmaceuticals PLC shares had held steady so far this quarter and gained 58.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.8% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 4 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Centessa Pharmaceuticals PLC is $41.50, about 4.3% above its last closing price of $39.72

This summary was machine generated from LSEG data April 1 at 04:30 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)